ERBB2 and hydrops fetalis: Similarly, during the first pivotal study of trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2), symptomatic HF or asymptomatic cardiac dysfunction developed in 27% of patients who received the drug in combination therapy (e.g., with traditional chemotherapy: doxorubicin and cyclophosphamide or radiation) [50].